Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Vemurafenib plus cobimetinib achieves significant progression-free survival in...

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Nivolumab shows signs of superior response rate compared to standard chemo in...

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

EORTC and the management of clinical trial data

Anastassia Negrouk - European Organisation for Research and Treatment of Cancer...

EORTC and the management of clinical trial data ( Anastassia Negrouk - European Organisation for Research and Treatment of Cancer, Brussels, Belgium and Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Improvements in progression free survival for patients with metastatic head and...

Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib ( Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium )

Financial impact of a cancer diagnosis

Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium

Financial impact of a cancer diagnosis ( Prof Françoise Meunier - Director General of EORTC, Brussels, Belgium )

Combining cobimetinib and vemurafenib improves progression-free survival in...

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Molecular targeting in cancer and the impact on personalised medicine

Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer...

Molecular targeting in cancer and the impact on personalised medicine ( Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

Cediranib and chemo combo improves PFS for metastatic cervical cancer

Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK

Cediranib and chemo combo improves PFS for metastatic cervical cancer ( Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK )

Phase III trial results raise questions about the future of lung cancer...

Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium

Phase III trial results raise questions about the future of lung cancer vaccination ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )

Little benefit for gefitinib-resistant lung cancer when continuing the drug...

Dr Tony Mok - The Chinese University of Hong Kong, Shatin, China

Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy ( Dr Tony Mok - The Chinese University of Hong Kong, Shatin, China )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

More from ecancer